Oragenics, Inc. Announces Private Placement (Business Wire)

Oragenics, Inc. Announces Private Placement

Oragenics, Inc., a UF startup and UF Innovate | Sid Martin Biotech graduate company dedicated to fighting infectious diseases including coronaviruses, announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the “Private Placement Offering”), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the “Common Stock”), and (ii) 404,728 shares of Series E Mirroring Preferred Stock (the “Series E Preferred Stock”).

The Company intends to propose an amendment to its Amended and Restated Articles of Incorporation, in connection with the Company’s annual meeting of shareholders, to effect an increase in the shares of Common Stock the Company is authorized to issue from 4,166,666 shares of Common Stock to 350,000,000 shares of Common Stock. The Series E Preferred Stock has super voting rights on the proposed amendment equal to 2,500 votes per share of Series E Preferred Stock.

Learn more about Oragenics, Inc. Announces Private Placement